Document and Entity Information Statement [Table] Statement [Line Items] Statement Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Debt Securities, Available-for-Sale, Current Short-term marketable securities Amount of receivable and asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Accounts Receivable, Prepaid Expense and Other Assets, Current Accounts receivable, prepaid expenses and other current assets Assets, Current Total current assets Debt Securities, Available-for-Sale, Noncurrent Marketable securities Property, Plant and Equipment, Net Property and equipment, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total accrued expenses Contract with Customer, Liability, Current Deferred income Deferred income, Current Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Other Liabilities, Noncurrent Other liabilities Contract with Customer, Liability, Noncurrent Deferred income, net of current portion Deferred income, Non-current Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration Liabilities Total liabilities Equity, Attributable to Parent [Abstract] Stockholders' Equity: Preferred Stock, Value, Issued Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2026 and December 31, 2025 Common Stock, Value, Issued Common stock, $0.00001 par value; 400,000,000 shares authorized at March 31, 2026 and December 31, 2025; 139,652,849 and 120,499,433 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Additional Paid in Capital Additional paidin capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Equity, Attributable to Parent Balance at end of period Balance at beginning of period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Shares, Issued Balance at end of period (in shares) Balance at beginning of period (in shares) Common stock, shares issued (in shares) Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Product and Service [Axis] Product and Service [Domain] Laboratory service revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered. Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts. Contract research Contract research License and Service [Member] Licensing License and Service Revenues [Abstract] Revenues: Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Operating Costs and Expenses [Abstract] Costs and expenses: Cost of Revenue Cost of revenue Research and Development Expense Research and development Total research and development General and Administrative Expense General and administrative Amount of payment to third parties recorded as licensing expenses. Licensing Expenses Licensing Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Revaluation of contingent consideration Change in value of contingent consideration Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Segment operating loss Other Nonoperating Income (Expense) [Abstract] Other income: Investment Income, Interest Interest income Royalty Income, Nonoperating Non-cash royalty income Nonoperating Income (Expense) Other income Total other income Net loss Net loss Earnings Per Share, Basic Net loss per share, basic Earnings Per Share, Diluted Net loss per share, diluted Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding, basic Weighted average shares of common stock outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding, diluted Weighted average shares of common stock outstanding, diluted Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive (loss) income: OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized (loss) gain on marketable securities, net of tax of $0 Other Comprehensive Income (Loss), Net of Tax Total other comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Unrealized gain on marketable securities, tax CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Retained Earnings [Member] Accumulated Deficit Sale of Stock [Axis] Sale of Stock [Domain] Information pertaining to an at the market offering of the entity's stock. At The Market Offering At the market offering Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of common stock in connection with vesting of restricted stock units Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of common stock in connection with vesting of restricted stock units (in shares) Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock under at-the-market sales agreement, net of offering costs of $1,884 Stock Issued During Period, Shares, New Issues Common stock, issued Issuance of common stock under at-the-market sales agreement, net of offering costs of $1,884 (In shares) Marketable Security, Unrealized Gain (Loss) Unrealized gain/loss on marketable securities APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Offering costs netted against proceeds CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Amount of increase (decrease) in accounts receivable, prepaid expenses and assets classified as other. Increase (Decrease) In Accounts Receivable, Prepaid Expense and Other Assets Accounts receivable, prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Increase (Decrease) in Contract with Customer, Liability Deferred income Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from sales and maturities of marketable securities The cash outflow for deferred transaction consideration to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Payment of Deferred Transactions Consideration to Acquire Intangible Assets Payments of deferred transaction consideration for in-licensed assets Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Sale of Stock, Consideration Received on Transaction Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs Payment, Tax Withholding, Share-Based Payment Arrangement Payments of employee withholding taxes related to restricted stock unit award vesting Proceeds from Stock Options Exercised Proceeds from exercise of employee stock options and the issuance of stock Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash investing activities: Capital Expenditures Incurred but Not yet Paid Additions to property and equipment included in accounts payable Organization and Nature of Business Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] Organization and Nature of Business Nature of Operations [Text Block] Organization and Nature of Business Summary of Significant Accounting Policies Schedule reflecting details about accounting policies. Summary Of Accounting Policies [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Summary Of Accounting Policies [Line Items] Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value of Financial Assets and Liabilities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets and Liabilities Measured at Fair Value Fair Value Disclosures [Text Block] Fair Value of Financial Assets and Liabilities Accrued Expenses The entire disclosure for accrued expenses and other liabilities that are classified as current at the end of the reporting period. Accrued Liabilities Disclosure Current [Text Block] Accrued Expenses Stockholders' Equity Equity [Text Block] Stockholders' Equity Stock-Based Awards Share-Based Payment Arrangement [Text Block] Stock-Based Awards Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Leases The entire disclosure of operating and finance leases. Lessee Operating And Finance Leases [Text Block] Leases No definition available. Agreements Related to Intellectual Property Collaborative Arrangement Disclosure [Text Block] Agreements Related to Intellectual Property No definition available. Sale of Future Royalties The entire disclosure of the royalty purchase agreement entered into by the company and the sale of future royalties. Royalty Purchase Agreement Disclosure [Text Block] Sale of Future Royalties Income Taxes Income Tax Disclosure [Text Block] Income Taxes Segment Information Segment Reporting Disclosure [Text Block] Segment Information Disclosure of accounting policy for the use of unaudited interim financial information. Unaudited Interim Financial Information Policy [Policy Text Block] Unaudited Interim Financial Information Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Reclassification, Comparability Adjustment [Policy Text Block] Reclassifications Disclosure of accounting policy for presentation of accounting policies in interim reports. Significant Accounting Policies [Policy Text Block] Significant Accounting Policies Disclosure of accounting policy for contingent consideration. Contingent Consideration, Policy [Policy Text Block] Contingent Consideration Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Disclosure of accounting policy for deferred income related to the sale of future royalties. Deferred Income Related to the Sale of Future Royalties Policy [Policy Text Block] Deferred Income Related to the Sale of Future Royalties Discontinued Operations, Policy [Policy Text Block] Discontinued Operations New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets and liabilities measured at fair value on a recurring and non-recurring basis Debt Securities, Available-for-Sale [Table Text Block] Schedule of the fair value of available for sale marketable securities Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of assumptions used to determine fair value of stock options granted Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of stock option activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Summary of restricted stock units activity Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of stock-based compensation expense Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders Lessee, Operating Leases [Text Block] Summary of supplemental balance sheet information related to operating leases Schedule of Segment Reporting Information, by Segment [Table Text Block] Summary of results of operations by segment Cash, Cash Equivalents, and Short-Term Investments Cash, cash equivalents and marketable securities Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Disposal Group, Including Discontinued Operation, Other Liabilities, Current Other current liabilities No definition available. Contingent Consideration [Abstract] Contingent Consideration Percentage of assets current stage of development and review. Percentage of Assets Current Stage of Development and Review Probability of success assumptions Percentage of discount rates applied to contingent payment. Percentage of Discount Rates Applied to Contingent Payment Discount range Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Inputs, Level 3 [Member] Level 3 Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Information pertaining to Confluence, an entity acquired by the entity. Confluence [Member] Confluence Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Debt Securities, Available-for-Sale Fair Value Marketable securities Assets, Fair Value Disclosure Total assets Liabilities, Fair Value Disclosure [Abstract] Liabilities: Commitments, Fair Value Disclosure Contingent consideration Liabilities, Fair Value Disclosure Total liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Transfers into or out of Level 3 Debt Securities, Available-for-Sale [Table] Financial Instrument [Axis] Financial Instruments [Domain] Corporate Debt Securities [Member] Corporate debt securities Fixed Income Securities [Member] Commercial paper US Treasury Securities [Member] Treasury bills US Government Agencies Debt Securities [Member] U.S. government debt securities Debt Securities, Available-for-Sale [Line Items] Fair value of the Company's available for sale marketable securities Debt Securities, Available-for-Sale [Abstract] Marketable securities: Debt Securities, Available-for-Sale, Amortized Cost Book Value Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Loss Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with maturity dates of a certain range. Debt Securities, Available-for-sale, Other Debt securities with maturity dates The maturity period of the marketable securities. Marketable Securities Maturity Period Marketable securities maturity period Employee-related Liabilities, Current Employee compensation expenses The liability for the aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. This is the portion of that liability expected to be paid within one year of the date of the statement of financial position. Accrued Research And Development Costs, Current Research and development expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for licensing expenses. Accrued Licensing Expenses Payable, Current Licensing expenses Other Accrued Liabilities, Current Other expenses Stock, Class of Stock [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] License and collaboration agreement for the development of products containing specified JAK inhibitors developed for the treatment of alopecia areata and other dermatological conditions. License and Collaboration Agreement Class of Stock [Line Items] Stockholders' Equity Number of votes for each share of common stock. Common Stock Number Of Votes Per Share Number of votes per share Dividends, Common Stock Dividends declared Class of Warrant or Right, Number of Securities Called by Warrants or Rights Common stock warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Initial exercise price Number of unexercised warrants. Class of Warrant or Right, Number of Securities Unexercised Warrants remained unexercised Proceeds from Issuance of Common Stock Aggregate gross proceeds Payments of Stock Issuance Costs Selling commissions and other fees Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to the 2025 Equity Incentive Plan provides for the grant of incentive stock options, non statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, cash-based awards and other stock-based awards. Equity Incentive Plan 2025 [Member] 2025 Equity Incentive Plan Represents information pertaining to 2024 Inducement Plan. Inducement Plan, 2024 [Member] 2024 Inducement Plan Information pertaining to the 2017 Inducement Plan, a non-shareholder approved stock plan adopted pursuant to the "inducement exception" provided under NASDAQ listing rules. The only persons eligible to receive grants of awards under the 2017 Inducement Plan are individuals who satisfy the standards for inducement grants under NASDAQ rules, generally including individuals who were not previously an employee or director of the Company. Under the terms of the 2017 Inducement Plan, the Company may grant up to 1,000,000 shares of common stock pursuant to nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit ("RSU") awards, and other stock awards. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2017 Inducement Plan will be added back to the shares of common stock available for issuance under the 2017 Inducement Plan. Equity Compensation 2017 Inducement Plan [Member] 2017 Inducement Plan The 2015 Equity Incentive Plan provides for the grant of incentive stock options, non statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, cash-based awards and other stock-based awards. Equity Incentive Plan 2015 [Member] 2015 Equity Incentive Plan Represents the information pertaining to awards remained available for grant under the 2015 Plan Awards Remained Available for Grant Under 2015 Plan [Member] Award remained available for grant under 2015 plan Represents the information pertaining to awards remained available for grant under the 2015 Plan and 2012 Plan. Awards Remained Available for Grant Under 2015 Plan and 2012 Plan [Member] Award remained available for grant under 2015 plan and 2012 plan Restricted Stock Units (RSUs) [Member] Restricted stock units Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock Based Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized Common Stock, Capital Shares Reserved for Future Issuance Common shares reserved for future issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Shares, ending balance Number of Shares, beginning balance Options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Stock Option Valuation Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Options, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of Shares, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of Shares, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of Shares, Forfeited and cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Number of Shares, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Number of Shares, Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, ending balance (in dollars per share) Weighted Average Exercise Price, beginning balance (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited and cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Options exercisable (in dollars per share) No definition available. Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract] Options, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Options vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Options exercisable (in years) N/A. Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate Intrinsic Value, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Aggregate Intrinsic Value, Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value of stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] RSU, Number of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Units outstanding, end of the year Units outstanding, beginning of the year Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Forfeited and cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] RSU, Weighted Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Ending balance (in dollars per share) Weighted Average Grant Date Fair Value, Beginning balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited and cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Aggregate intrinsic value of awards that vested during the period Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Cost of Sales [Member] Cost of revenue Research and Development Expense [Member] Research and development General and Administrative Expense [Member] General and administrative An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Employee Consultants and Directors Stock Options [Member] Options to purchase common stock Stock options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation expense Share-Based Payment Arrangement, Expense Total stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense, options Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized stock-based compensation expense, RSUs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average recognition period unrecognized stock-based compensation cost (in years) Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Net Loss per Share Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Basic and diluted net loss per share attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Denominator: Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Loss per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders Lessee, Lease, Description [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Representing information pertaining to operating leases. Operating Leases Lessee, Lease, Description [Line Items] Leases Net Rentable Area Area leased, sublease agreement No definition available. Operating Leases [Abstract] Operating Leases: Amount, before accumulated amortization, of right-of-use asset from operating lease. Operating Lease, Right-of-Use Asset, before Accumulated Amortization Gross cost Amount of accumulated amortization of right-of-use asset from operating lease. Operating Lease, Right-of-Use Asset, Accumulated Amortization Accumulated amortization Operating Lease, Right-of-Use Asset Other assets Operating Lease, Liability, Current Current portion of lease liabilities Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Financial position Operating Lease, Liability, Noncurrent Other liabilities Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Financial position Operating Lease, Liability Total operating lease liabilities The amount of amortization expenses in connection with operating leases. Operating Leases Amortization Expense Amortization expense Collaborative Arrangement and Arrangement Other than Collaborative [Table] Represents information relating to patent license agreement. Patent License Agreement [Member] Patent License Agreement Represents information pertaining to asset purchase agreement encompassing worldwide rights to oxymetazoline hydrochloride cream plus intellectual property. APA Asset Purchase Agreement This member stands for Agreement and Plan of Merger. Agreement and Plan of Merger Agreement and Plan of Merger - Confluence Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Sun Pharmaceutical Industries, Inc. Sun Pharmaceutical Industries, Inc [Member] Sun Pharmaceutical Industries, Inc Represents information relating to Eli Lilly and Company. Eli Lilly and Company Eli Lilly and Company Scenario [Axis] Scenario [Domain] Pertaining to the achievement of specified regulatory milestones. Achievement Of Specified Regulatory Milestones Pertaining to achievement of specified sales milestones. Achievement Of Specified Sales Milestones [Member] Achievement Of Specified Sales Milestones Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Agreements Related to Intellectual Property Sale of Future Royalties The amount of cash outflow for payment of upfront consideration. Payment Of Upfront Consideration Upfront cash amount The amount of development costs reimbursed during the period. Development Costs Reimbursed Development costs of reimbursement The amount of cash outflow associated for license payments. Payment of License Costs Cash payments The value of contingent consideration to be payable upon achievement of certain milestones. Contingent Consideration Payable Upon Achievement Of Certain Milestones Achievement of specified regulatory milestones The cash inflow associated with the amount received for regulatory and commercial milestones. Regulatory and Commercial Milestones, Payments Received Regulatory and commercial milestones Percentage of sale of EPI Health cream. Percentage Of Sale Of Epi Health Cream Percentage of Sale of EPI Health Cream In a business combination, the maximum contingent consideration to be paid based upon achievement of certain milestones as set forth in the Agreement and Plan of Merger. Business Combination Maximum Contingent Consideration Milestone Payments Per Agreement Additional contingent consideration based on milestones, maximum, per Agreement The term of agreement. Agreement Term, Duration Term of agreement Represents information pertaining to Ontario Municipal Employees Retirement System. Ontario Municipal Employees Retirement System [Member] OMERS Represents information pertaining to royalty purchase agreement. Royalty Purchase Agreement [Member] Royalty purchase agreement Legal Entity [Axis] All Entities [Member] Royalty [Member] Non-cash royalty Amount of cash inflow from upfront payment received pursuant to the agreement. Proceeds From Upfront Payment Proceeds from upfront payment The percent of remaining anniversary milestone payments payable acquired pursuant to the agreement. Percentage of Remaining Anniversary Milestone Payments Payable Acquired Percentage of remaining anniversary milestone payments payable acquired Federal Income Tax Expense (Benefit), Continuing Operations Federal income tax benefit State and Local Income Tax Expense (Benefit), Continuing Operations State income tax benefit Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segment loss before income taxes Loss before income taxes Schedule of Segment Reporting Information, by Segment [Table] Information pertaining to segment that earns revenue from the provision of laboratory services to clients through Confluence, the Company's wholly-owned subsidiary. Laboratory service revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis. Contract Research Segment Contract Research Segment Information pertaining to dermatology therapeutics segment, which is focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Dermatology Therapeutics Segment Licensing revenue Represents the information pertaining to drug candidate being Bosakitug. Drug Candidate, Bosakitug [Member] Bosakitug Represents the information pertaining to drug candidate being ATI-052. Drug Candidate, ATI-052 [Member] ATI-052 Represents the information pertaining to drug candidate being ATI-2138. Drug Candidate, ATI-2138 [Member] ATI-2138 Represents the information pertaining to drug candidate being ATI-9494. Drug Candidate, ATI-9494 [Member] ATI-9494 Represents the information pertaining to drug discovery platform.. Drug Discovery Platform [Member] Discovery Segments [Axis] Segments [Domain] Represents the member information pertaining to single reportable segment. Single Reportable Segment [Member] Single reportable segment Segment Reporting Information [Line Items] Segment Information Number of Reportable Segments Number of reportable segments The amount of cost if revenue excluding restructuring expense. Cost Of Revenue Excluding Restructuring Expense Cost of revenue The amount of research and development related to project. Research and Development, Project Spend Total research and development project expense The amount of research and development expense related to personnel charges. Research and Development Expense, Personnel Charges Personnel The amount of research and development expense, classified as other. Research and Development Expense, Other Other research and development No definition available. Rule 10b5-1 Arrangement Modified [Flag] Rule 10b5-1 Arrangement Modified No definition available. Non-Rule 10b5-1 Arrangement Modified [Flag] Non-Rule 10b5-1 Arrangement Modified